Wallace D, et al. LSM. 2016. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.View Publication
Merrill J, et al. LSM 2018 – Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.
Ramsey-Goldman R, et al. LSM 2017 • Cell-bound complement activation products in SLE.
Buyon J, et al. LSM 2016 – Reduction in EC4d and anti-C1q antibodies associate with clinical improvement in SLE.
Wallace D, et al. LSM. 2016. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.
February 2016 • Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.
November 2016 • The AVISE Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus.
May 2015 • Diagnosing Connective Tissue Disease in Clinical Practice.
Putterman C, et al. LSM. 2014. Cell_bound complement activation products in systemic lupus erythematosus.
August 2014 • Finding the Best Approach to Autoimmune Connective Tissue Disease Diagnosis.
September 2014 • Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements.
2013 • An Assay Panel Combining Cell-Bound Complement Activation Products With Autoantibodies to Extractable Nuclear Antigens and Mutated Citrullinated Vimentin Helps With the Differential Diagnosis of Systemic Lupus Erythematosus.
November 2013 • Diagnosis of Lupus in the New Age of Biomarkers: Part II- New and Emerging Biomarker Technology in the Diagnosis of Lupus.
September 2013 • Diagnosis of Lupus in the New Age of Biomarkers: Part I- Meeting Diagnostic Challenges in Lupus with Cell-Bound Complement Activation Products.
2013 • Best Practices In: Identification and Diagnostics of Connective Tissue Disease.
December 2012 • Measurement of Cell-Bound Complement Activation Products Enhances Diagnostic Performance in Systemic Lupus Erythematosus.
October 2005 • Reticulocytes Bearing C4d as Biomarkers of Disease Activity for Systemic Lupus Erythematosus.
Methotrexate polyglutamates (MTXPGs)
2005 • Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study.
2006 • Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.
2004 • Toward a better understanding of methotrexate.
Anti-Carbamylated Protein Antibodies (Anti-CarP)
Shi J, et al. Arthritis & Rheumatism 2013. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage.View Publication
An Evaluation of the Economic Impact of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using Complement C4D Activation Products in a Multivariate Assay.
ACR Chicago 2018. Genetic Polymorphism in Dihydrofolate Reductase Impacts Methotrexate Polyglutamation in Adult Rheumatoid Arthritis
ACR Chicago 2018 • Complement C4d Split Products in Combination With lupus Anticoagulant and Low Complement Associate With Thrombosis in Systemic lupus erythematosus
ACR Chicago 2018 • Diagnostic Performances of Antibodies Against Carbamylated Proteins in U.S. Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases
ACR San Diego 2017. Abnormalities in Complement System are Related to Disease Severity Index in Systemic lupus erythematosus